Compare Stocks

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$24.75 -3.2%	$13.01	$5.00 ▼ $27.90	$26.24M	1.66	17,042 shs	18,321 shs
CEMI Chembio Diagnostics	$0.46	$0.43	$0.19 ▼ $1.24	$16.71M	1.85	661,416 shs	351,642 shs
GLS Gelesis		$0.21	$0.11 ▼ $5.71	$11.63M	0.88	386,034 shs	185,100 shs
LMNL Liminal BioSciences	$8.50 +0.1%	$8.47	$3.10 ▼ $8.50	$26.35M	1.03	63,470 shs	5,000 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-3.21%	+13.27%	+111.36%	+246.15%	+59.61%
CEMI Chembio Diagnostics	0.00%	0.00%	0.00%	0.00%	+1.16%
GLS Gelesis	0.00%	0.00%	0.00%	0.00%	0.00%
LMNL Liminal BioSciences	0.00%	0.00%	0.00%	0.00%	+25.37%

AI “wealth window” is closing soon! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXN Addex Therapeutics	1.0301 of 5 stars	0.0	5.0	0.0	0.0	3.3	0.8	0.6
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GLS Gelesis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	2.00	Hold	N/A	N/A
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A
GLS Gelesis	N/A	N/A	N/A	N/A
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$1.51M	17.37	N/A	N/A	$8.01 per share	3.09
CEMI Chembio Diagnostics	$48.34M	0.35	N/A	N/A	$0.48 per share	0.95
GLS Gelesis	$25.77M	0.00	N/A	N/A	($0.34) per share	0.00
LMNL Liminal BioSciences	$310K	85.00	N/A	N/A	$8.97 per share	0.95

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	-$21.80M	-$19.27	N/A	N/A	N/A	-550.78%	-236.83%	-147.15%	5/9/2024 (Estimated)
CEMI Chembio Diagnostics	-$23.29M	-$1.20	N/A	∞	N/A	-47.03%	-113.57%	-38.22%	N/A
GLS Gelesis	-$56.03M	-$1.40	N/A	N/A	N/A	-221.38%	N/A	-14.98%	N/A
LMNL Liminal BioSciences	$380K	$0.29	29.31	∞	N/A	248.35%	-88.44%	-64.15%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A
GLS Gelesis	N/A	N/A	N/A	N/A	N/A
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	2.97	2.97
CEMI Chembio Diagnostics	N/A	1.23	1.04
GLS Gelesis	N/A	0.30	0.21
LMNL Liminal BioSciences	0.02	2.78	2.78

Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
CEMI Chembio Diagnostics	8.65%
GLS Gelesis	16.71%
LMNL Liminal BioSciences	0.66%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
CEMI Chembio Diagnostics	3.30%
GLS Gelesis	11.90%
LMNL Liminal BioSciences	2.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	24	1.06 million	901,000	Not Optionable
CEMI Chembio Diagnostics	337	36.73 million	35.51 million	Not Optionable
GLS Gelesis	2	73.33 million	64.61 million	Not Optionable
LMNL Liminal BioSciences	251	3.10 million	3.04 million	Not Optionable

ADXN, LMNL, CEMI, and GLS Headlines

Source	Headline
	Liminal unveils institutional custody offering for digital asset solutions financialexpress.com - March 6 at 3:51 PM
	LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP finance.yahoo.com - September 26 at 12:19 PM
	Liminal BioSciences Inc.: LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP finanznachrichten.de - September 19 at 7:57 PM
	Liminal BioSciences gets final order for the Structured Alpha takeover msn.com - September 19 at 7:57 PM
	LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP finance.yahoo.com - September 19 at 7:57 PM
	LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP finance.yahoo.com - September 15 at 2:15 PM
	Liminal BioSciences Inc.: LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR finanznachrichten.de - September 12 at 7:16 PM
	LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR finance.yahoo.com - September 12 at 7:16 PM
	Liminal BioSciences shareholders to vote on takeover deal Sept. 15 msn.com - August 16 at 8:28 PM
	LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP finance.yahoo.com - August 16 at 8:28 PM
	Liminal BioSciences Inc.: Liminal BioSciences Reports Second Quarter Financial Results 2023 finanznachrichten.de - August 8 at 7:05 PM
	Liminal BioSciences Reports Second Quarter Financial Results 2023 finance.yahoo.com - August 8 at 7:05 PM
	Limina BioSciences annonce la conclusion d'un accord avec Structured Alpha LP prnewswire.com - July 13 at 8:05 PM
	Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder finance.yahoo.com - July 13 at 3:39 PM
	Liminal BioSciences Accepts $8.50 a Share Buyout Offer From Structured Alpha marketwatch.com - July 12 at 6:23 PM
	LMNL Skyrockets on Acquisition by Structured Alpha msn.com - July 12 at 1:22 PM
	Liminal BioSciences Stock Gains0% Today - Here's Why? benzinga.com - July 12 at 1:22 PM
	Liminal BioSciences Inc.: Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP finanznachrichten.de - July 12 at 8:22 AM
	Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management msn.com - July 12 at 8:22 AM
	Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP finance.yahoo.com - July 12 at 8:22 AM
	Liminal Biosciences announces preclinical pipeline progress bioworld.com - June 7 at 8:54 PM
	Liminal BioSciences Inc.: Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders finanznachrichten.de - June 5 at 6:21 PM
	Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders finance.yahoo.com - June 5 at 6:21 PM
	Liminal BioSciences Inc.: Liminal BioSciences Provides R&D Update finanznachrichten.de - June 2 at 10:48 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Addex Therapeutics

NASDAQ:ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Chembio Diagnostics

NASDAQ:CEMI

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Gelesis

NYSE:GLS

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Liminal BioSciences

NASDAQ:LMNL

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial